Press release

DSM announces change of leadership for Biomedical

Exton PA, US, 16 Nov 2015 18:00 CET

Royal DSM, a global science-based company active in health, nutrition and materials today announces a change in the leadership of its DSM Biomedical unit. Christophe Dardel, President DSM Biomedical will pursue his career outside DSM.

To ensure the continuing progress in Biomedical, Mr. Gerard de Reuver will assume responsibility for DSM Biomedical with immediate effect until a long-term successor is appointed.

Gerard, a Dutch national, joined DSM in 2002 after obtaining a University degree in Pharmacy & Biology and gaining senior leadership experience at amongst others Pfizer, Unilever, Perstorp, Gemini and Perkin Elmer. He held positions as President DSM Anti-Infectives and Vice President Crisis & Change. From April 2010 until August 2015, he held the position of President DSM Dyneema and played a key role in developing and strengthening the DSM Dyneema organization.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Global Director External Communications

Herman Betten

+31 45 578 2420

DSM Investor Relations

Dave Huizing

+31 45 578 2864

Read more

  • Our products

    DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.

  • The markets we serve

    DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.

This site uses cookies to store information on your computer.

Learn more